Humasis Co

Humasis Co EBITDA per Share

The EBITDA per Share of Humasis Co (205470.KQ) as of Nov 11, 2026 is -440.84 KRW. In the previous year, EBITDA per Share was -1,385.21 KRW — a change of -68.17% (higher).

EBITDA per Share

-440.84KRW

YoY

-68.17%

Last updated:

EBITDA per Share of Humasis Co is 2025 -440.84 KRW. EBITDA per Share of Humasis Co was 2024 -1,385.21 KRW. It decreases by -68.17% higher compared to the previous year.

The Humasis Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-30.29 KRW
Jan 1, 2019
-24.80 KRW
Jan 1, 2020
803.59 KRW
Jan 1, 2021
6,180.33 KRW
Jan 1, 2022
6,582.74 KRW
Jan 1, 2023
-1,875.68 KRW
Jan 1, 2024
-1,385.21 KRW
Jan 1, 2025
-440.84 KRW
The Humasis Co EBITDA per Share history
YEAREBITDA per ShareYoY
-440.84KRW-68.17%
-1,385.21KRW-26.15%
-1,875.68KRW-128.49%
6,582.74KRW+6.51%
6,180.33KRW+669.09%
803.59KRW-3,339.88%
-24.80KRW-18.10%
-30.29KRW+1,294.47%
-2.17KRW+48.15%
-1.47KRW-11.29%
-1.65KRW+32.43%
-1.25KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

EBITDA per Share of Humasis Co is -440.84 KRW in 2025.

EBITDA per Share of Humasis Co changed from -1,385.21 KRW to -440.84 KRW, representing a -68.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Humasis Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Humasis Co

All Key Metrics — Humasis Co